Filing Flows › Tonix Pharmaceuticals Holding (TNXP) › Q2 2026
Tonix Pharmaceuticals Holding (TNXP) Q2 2026 earnings results (second quarter 2026)
10-Q filed Aug 10, 2026
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $13.5M for the second quarter 2026 (Q2 2026), +578% from a year earlier and +97% from the quarter before. Operating margin was -314.1%, net loss $40.6M (299.4% of revenue).
Tonix Pharmaceuticals Holding, Q2 2026: revenue $13.5M (+578% year over year), operating margin -314.1%, net loss $40.6M, operating cash flow −$42.2M. The chart follows the revenue to costs, profit and cash.
| Q2 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $13.5M | +97% | +578% |
| Operating profit | −$42.5M | — | — |
| Net earnings | −$40.6M | — | — |
| Operating cash flow | −$42.2M | — | — |
What changed
Revenue was $13.5M in Q2 2026, up 578% year over year and up 97% from the previous quarter. Tonmya was the largest line at 81% of revenue. Zembrace Symtouch added $426K year over year (up 27%), 4% of the total change.
Operating costs exceeded revenue by $42.5M, an operating margin of -314.1%. Total costs grew 85% against revenue growth of 578%. The fastest-growing cost line was SG&A (+122%). The quarter ended with a net loss of $40.6M, wider than the previous quarter's $40.2M loss.
Operating cash flow was −$42.2M. Non-cash charges added back $619K of depreciation and amortization and $2.3M of share-based compensation. Working capital and other items used $4.6M. Capital expenditures of $587K exceeded it, leaving free cash flow of −$42.8M.
Questions
What was Tonix Pharmaceuticals Holding's revenue in the second quarter 2026?
Tonix Pharmaceuticals Holding (TNXP) reported revenue of $13.5M for the second quarter 2026 (Q2 2026), +578% from a year earlier and +97% from the quarter before.
Was Tonix Pharmaceuticals Holding profitable in the second quarter 2026?
Operating loss was $42.5M (-314.1% of revenue) and net loss $40.6M.